These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26160441)

  • 21. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation.
    Ytterberg AJ; Joshua V; Reynisdottir G; Tarasova NK; Rutishauser D; Ossipova E; Haj Hensvold A; Eklund A; Sköld CM; Grunewald J; Malmström V; Jakobsson PJ; Rönnelid J; Padyukov L; Zubarev RA; Klareskog L; Catrina AI
    Ann Rheum Dis; 2015 Sep; 74(9):1772-7. PubMed ID: 24817415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin.
    Vossenaar ER; Després N; Lapointe E; van der Heijden A; Lora M; Senshu T; van Venrooij WJ; Ménard HA
    Arthritis Res Ther; 2004; 6(2):R142-50. PubMed ID: 15059278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis.
    Feitsma AL; van der Voort EI; Franken KL; el Bannoudi H; Elferink BG; Drijfhout JW; Huizinga TW; de Vries RR; Toes RE; Ioan-Facsinay A
    Arthritis Rheum; 2010 Jan; 62(1):117-25. PubMed ID: 20039411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs.
    Figueiredo CP; Bang H; Cobra JF; Englbrecht M; Hueber AJ; Haschka J; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Henes J; Krueger K; Rech J; Schett G
    Ann Rheum Dis; 2017 Feb; 76(2):399-407. PubMed ID: 27323772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis.
    Brink M; Hansson M; Mathsson L; Jakobsson PJ; Holmdahl R; Hallmans G; Stenlund H; Rönnelid J; Klareskog L; Rantapää-Dahlqvist S
    Arthritis Rheum; 2013 Apr; 65(4):899-910. PubMed ID: 23310951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis.
    Huang J; Zeng T; Zhang X; Tian Y; Wu Y; Yu J; Pei Z; Liu Y; Hu T; Tan L
    Br J Biomed Sci; 2020 Jan; 77(1):19-23. PubMed ID: 31433746
    [No Abstract]   [Full Text] [Related]  

  • 28. Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis.
    Ishigooka N; Fujii T; Abe H; Murakami K; Nakashima R; Hashimoto M; Yoshifuji H; Tanaka M; Ito H; Ohmura K; Morita S; Mimori T
    Mod Rheumatol; 2020 May; 30(3):450-457. PubMed ID: 31116051
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Toes RE; Huizinga TW
    Arthritis Res Ther; 2005; 7(5):R949-58. PubMed ID: 16207336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis.
    Geraldino-Pardilla L; Russo C; Sokolove J; Robinson WH; Zartoshti A; Van Eyk J; Fert-Bober J; Lima J; Giles JT; Bathon JM
    Rheumatology (Oxford); 2017 Apr; 56(4):534-540. PubMed ID: 27994093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.
    Nicaise-Roland P; Nogueira L; Demattei C; de Chaisemartin L; Rincheval N; Cornillet M; Grootenboer-Mignot S; Dieudé P; Dougados M; Cantagrel A; Meyer O; Serre G; Chollet-Martin S
    Ann Rheum Dis; 2013 Mar; 72(3):357-62. PubMed ID: 22580581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis.
    Poulsom H; Charles PJ
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):4-10. PubMed ID: 18270850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis.
    Ospelt C; Bang H; Feist E; Camici G; Keller S; Detert J; Krämer A; Gay S; Ghannam K; Burmester GR
    Ann Rheum Dis; 2017 Jul; 76(7):1176-1183. PubMed ID: 28183721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    Rheumatology (Oxford); 2008 Oct; 47(10):1489-92. PubMed ID: 18703528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hearing impairment in patients with rheumatoid arthritis: association with anti-citrullinated protein antibodies.
    Lobo FS; Dossi MO; Batista L; Shinzato MM
    Clin Rheumatol; 2016 Sep; 35(9):2327-32. PubMed ID: 27112144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis.
    Shi J; van de Stadt LA; Levarht EW; Huizinga TW; Toes RE; Trouw LA; van Schaardenburg D
    Arthritis Rheum; 2013 Apr; 65(4):911-5. PubMed ID: 23279976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide.
    El-Barbary AM; Kassem EM; El-Sergany MA; Essa SA; Eltomey MA
    J Rheumatol; 2011 May; 38(5):828-34. PubMed ID: 21362765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance of 14-3-3η and anti-carbamylated protein antibodies in Rheumatoid Arthritis in Han population of Northern China.
    Zhang Y; Liang Y; Feng L; Cui L
    Clin Chim Acta; 2020 Mar; 502():102-110. PubMed ID: 31862264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls.
    Koppejan H; Trouw LA; Sokolove J; Lahey LJ; Huizinga TJ; Smolik IA; Robinson DB; El-Gabalawy HS; Toes RE; Hitchon CA
    Arthritis Rheumatol; 2016 Sep; 68(9):2090-8. PubMed ID: 26946484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies.
    Jiang X; Trouw LA; van Wesemael TJ; Shi J; Bengtsson C; Källberg H; Malmström V; Israelsson L; Hreggvidsdottir H; Verduijn W; Klareskog L; Alfredsson L; Huizinga TW; Toes RE; Lundberg K; van der Woude D
    Ann Rheum Dis; 2014 Oct; 73(10):1761-8. PubMed ID: 24812286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.